



The Michael J. Fox Foundation for Parkinson's Research & The New York Academy of Sciences
Parkinson's Disease Therapeutics Conference
New York, NY
October 6, 2010

Oct 6, 2010	
8.30	Breakfast
9.00 – 9.30	Welcome by Katie Hood and Franz Hefti, PhD
9.30 – 10.20	<p>Novel Therapeutic Targets</p> <p><i>Patrick Little, PhD, Adolor Corporation</i> "Optimization of MOR Antagonists for the Treatment of L-DOPA-Induced Dyskinesias in Parkinson's Disease"</p> <p><i>Erwan Bezard, PhD, Université de Bordeaux</i> "Functional Inhibition of RasGRF1 in the MPTP-lesioned NHP Model for Treating Levodopa-induced Dyskinesia"</p>
10.20 – 10.50	Networking Break/Poster Viewing
10:50 – 12.30	<p>Novel Therapeutic Targets (cont'd)</p> <p><i>Gerard Griffioen, PhD, reMYND NV</i> "Pharmacodynamics of ReS9-S7, A First-in-class, Disease-modifying Drug Candidate for Treatment of Parkinson's Disease"</p> <p><i>Gregory A. Petsko, PhD, Brandeis University</i> "Specific Inhibition of Nucleation of Alpha-synuclein Aggregation as a Therapeutic Strategy"</p> <p><i>R. Jeremy Nichols, PhD, The Parkinson's Institute</i> "Identification of Substrates and Development of a Cell Based Assay for LRRK2"</p> <p><i>Raymond T. Bartus, PhD, Ceregene, Inc.</i> "A Clinical Trial of Neurturin (NTN) Gene Therapy for PD"</p>
12.30 – 1.45	Lunch/Poster Viewing
1.45 – 3.00	<p>Research Tools and Resources</p> <p><i>Kenneth Marek, MD, Institute for Neurodegenerative Disorders</i> "The Parkinson's Progression Markers Initiative"</p> <p><i>Samuel M. Goldman, MD, The Parkinson's Institute</i> "Assessing Heart Rate Variability (HRV) in the Parkinson's Associated Risk Study (PARS) Cohort"</p>

	<p><i>David E. Vaillancourt, PhD, University of Illinois at Chicago</i> “High Resolution Diffusion Tensor Imaging in Parkinson's Disease and Parkinson Plus Syndromes”</p>
3.00 – 3.30	Networking Break/Poster Viewing
3.30 – 4.45	<p>Hot Topics in Parkinson’s Disease Research</p> <p><i>Kalpana Merchant, PhD, Eli Lilly & Co.</i> “Animal Models of PD: Are they Translational Enough to Aid Drug Discovery?”</p> <p><i>Russell Katz, MD, US Food & Drug Administration</i> “FDA Requirements for Disease-Modification”</p>
4.45 – 5.00	Closing Remarks
4.45. – 7.00	Cocktail Reception/Poster Viewing